Gregory Jicha, MD
Neurology · Lexington, KYNPI 1619073202
Payments from drug & device makers
Across 730 payments — averaging $9721.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$3.9M
- AbbVie$1.2M
- Eli Lilly$903K
- Novartis$842K
- Novo Nordisk AS$177K
- Alnylam Pharmaceuticals Inc.$104K
- plus $29K from 2 others
Across 3 payments — averaging $368.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$980
- AbbVie$124
What the payments were for
- Travel & lodging$1,00072%
- Food & beverage$38428%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 532 | $3,851,572 |
| AbbVie | 72 | $1,189,633 |
| Eli Lilly | 19 | $902,988 |
| Novartis | 5 | $841,512 |
| Novo Nordisk AS | 50 | $177,350 |
| Alnylam Pharmaceuticals Inc. | 49 | $104,387 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27,115 |
| Genentech, Inc. | 2 | $2,256 |
How this compares
$7,096,814 in reported general payments places this provider in the 95th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 74 | $19,728 |
| Memantine Hcl | 354 | $10,292 |
| Memantine Hcl ErMemantine Hcl | 32 | $5,491 |
| Donepezil Hcl | 371 | $3,389 |
| Mirtazapine | 85 | $1,020 |
| Escitalopram Oxalate | 92 | $777 |
| Lamotrigine | 56 | $668 |
| Quetiapine Fumarate | 42 | $568 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $454 |
| Primidone | 21 | $276 |
| Levetiracetam | 33 | $275 |
| Duloxetine Hcl | 23 | $270 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $238 |
| Trazodone Hcl | 29 | $227 |
| Gabapentin | 14 | $188 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lexington
- James WinkleyLexington$1.9M
- John SlevinLexington$984K
- Nicole EvermanLexington$834K
- Zabeen MahuwalaLexington$694K
- Toufic FakhouryLexington$326K
- Jagannadha AvasaralaLexington$177K
- Edward KasarskisLexington$121K
- Meriem Bensalem-OwenLexington$65K
- Zain GuduruLexington$39K
- Fred OdagoLexington$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.